Patient-reported outcomes (PROs) in KEYNOTE-002, a randomized study of pembrolizumab vs chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) metastatic melanoma (MEL).
Dirk Schadendorf(National Center for Tumor Diseases), Antoni Ribas(University of California, Los Angeles), Jacob Schachter, Omid Hamid(Cedars-Sinai Medical Center), Axel Hauschild(University Hospital Schleswig-Holstein), Igor Puzanov(Roswell Park Comprehensive Cancer Center), Alfons J. van den Eertwegh(Amsterdam UMC Location Vrije Universiteit Amsterdam), Lee D. Cranmer(University of Washington), Steven O’Day(Saint John's Health Center), Carmen Loquai(Johannes Gutenberg University Mainz), Christian U. Blank(The Netherlands Cancer Institute), Reinhard Dummer(University Hospital of Zurich), April K.S. Salama(Duke University), Caroline Robert(Institut Gustave Roussy), Yang Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Janice M. Mehnert(NYU Langone Health), Wei Zhou(Broad Institute), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Soonmo Peter Kang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Adil Daud(University of California, San Francisco)
Cited by 2
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k